Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015 ; 373 : 2117.
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017 ; 377 : 644.
Tanaka H, Takano K, Iijima H, et al. Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus. Adv Ther 2017 ; 34 : 436.
Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events : Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2017 Nov 13. pii : CIRCULATIONAHA.117.032038. doi : 10.1161/CIRCULATIONAHA.117.032038.
Roussel R, Steg PG, Mohammedi K, et al. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes : A perspective on glucose-lowering interventions. Diabetes Obes Metab. 2017 Jun 9. doi : 10.1111/dom.13033.